Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
03
2020
revised:
05
05
2020
accepted:
02
06
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
epublish
Résumé
Second line of treatment of hepatocellular carcinoma (HCC) has notably changed in recent years as three novel drugs with a different mechanism of action have demonstrated to improve survival compared to placebo; thus, there is a need to better define the profile of optimal candidates to second-line treatment with these drugs in order to maximize clinical benefit. We performed a pooled analysis from the subgroup analysis of all published phase III trials for approved targeted therapy in the second line of treatment for HCC, with the aim to discover possible clinical-pathological predictive factors. Four studies were included in the analysis for a total of 2137 cases whose results supported the use of these novel agents in male patients with ECOG: 0, extrahepatic metastases, and HBV infection. Future studies are awaited to define best candidates for novel agents approved in the second line of treatment for HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Second line of treatment of hepatocellular carcinoma (HCC) has notably changed in recent years as three novel drugs with a different mechanism of action have demonstrated to improve survival compared to placebo; thus, there is a need to better define the profile of optimal candidates to second-line treatment with these drugs in order to maximize clinical benefit.
MATERIALS AND METHODS
METHODS
We performed a pooled analysis from the subgroup analysis of all published phase III trials for approved targeted therapy in the second line of treatment for HCC, with the aim to discover possible clinical-pathological predictive factors.
RESULTS
RESULTS
Four studies were included in the analysis for a total of 2137 cases whose results supported the use of these novel agents in male patients with ECOG: 0, extrahepatic metastases, and HBV infection.
CONCLUSIONS
CONCLUSIONS
Future studies are awaited to define best candidates for novel agents approved in the second line of treatment for HCC.
Identifiants
pubmed: 32655640
doi: 10.1155/2020/8024124
pmc: PMC7321521
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8024124Informations de copyright
Copyright © 2020 Giandomenico Roviello et al.
Déclaration de conflit d'intérêts
All authors declare that there are no conflicts of interest in this work.
Références
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
J Hepatol. 2019 Jun;70(6):1262-1277
pubmed: 30943423
Lancet Oncol. 2015 Jul;16(7):859-70
pubmed: 26095784
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514